Research Projects

Glioblastoma multi-form GBM is the most common form of gliomas in adults, accounting for 54 of all gliomas and 16 of primary brain tumors. Traditionally, treatment involves surgery, chemotherapy, and radiotherapy, with temozolomide (TMZ) being the first line drug. However, GBM's invasive nature prevents complete surgical removal, leading to recurrence, resistance, and death. Novel strategies for treating GBM include targeted therapies, radiotherapy, immunotherapies, targeted agents, and radiation modalities. A nanoparticle-based TMZ system is needed to improve solubility, stability, and effectivity, targeting GBM-specific cells and addressing challenges in brain delivery. This project aims to design Gint4.T aptamer conjugated polyamidoamine PAMAM dendrimers for the encapsulation and targeting of TMZ to the brain. Nanotechnology has shown potential in treating gliomas and GBM, targeting anti-GBM drugs and genes, and imaging. Previous research has shown that nanocarriers can cross the blood-brain barrier, providing hope for new nanomedicine combinations and nanotheranostics options. The proposed nano-formulation aims to improve the solubility and half-life of TMZ, a key drug for glioblastoma, and improve its clinical applications.